This story has been updated to include additional manufacturing capabilities of authorized reagent suppliers.
NEW YORK – Labs developing their own assays for SARS-CoV-2 virus detection in patients are coming across unexpected bottlenecks and hurdles as they rush toward US Food and Drug Administration emergency use authorization.